Alipogene tiparvovec, an adeno-associated virus encoding the Ser 447X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 6, 2009, Pages 681-691

  Burnett, John R ^a,b   Hooper, Amanda J ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPOGENE TIPARVOVEC; GLYBERA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; PROTEIN; SERINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VIRUS VECTOR;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADENO ASSOCIATED VIRUS; AUTOSOMAL DISORDER; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERLIPOPROTEINEMIA TYPE 5; HYPERTRIGLYCERIDEMIA; LOW DRUG DOSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PANCREATITIS; PROTEIN BLOOD LEVEL; REVIEW; SYNDROME X; TRIACYLGLYCEROL BLOOD LEVEL; VIRAL GENE THERAPY; WILD TYPE; XANTHOMATOSIS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENE THERAPY; GENETIC VECTORS; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; LIPOPROTEIN LIPASE; MICE; SERINE;

ADENO-ASSOCIATED VIRUS;

EID: 72449169616     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Amsterdam Molecular Therapeutics strengthens lipoprotein lipase gene therapy program. Amsterdam Molecular Therapeutics BV PRESS RELEASE 2001 August 20
2. Working towards clinical application of gene therapy for LPL deficiency. Rip J, Nierman MC, Sierts JA, Raalte van D, Petersen W, van den Oever K, Ross CJ, Hayden MR, Meulenberg JM, Twisk J, Kastelein JJP et al CIRCULATION 2003 108 17 Suppl 4 Abs 628
3. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. Weinstock PH, Bisgaier CL, Aalto-Setala K, Radner H, Ramakrishnan R, Levak-Frank S, Essenburg AD, Zechner R, Breslow JL J CLIN INVEST 1995 96 6 2555-2568
4. AMT obtains Orphan Drug designation for its LPL gene therapy product. Amsterdam Molecular Therapeutics BV PRESS RELEASE 2004 March 17
5. Amsterdam Molecular Therapeutics BV (AMT) acquires license to AAV patents from Targeted Genetics Corporation. Amsterdam Molecular Therapeutics BV PRESS RELEASE 2006 December 12
6. Amsterdam Molecular Therapeutics announces intention to launch an Initial Public Offering (IPO) on Euronext Amsterdam. Amsterdam Molecular Therapeutics BV PRESS RELEASE 2007 May 22
7. AMT presents positive results of phase I/II study with lead product at annual meeting of American Society of Gene Therapy. Amsterdam Molecular Therapeutics BV PRESS RELEASE 2007 May 31
8. AMT receives Orphan Drug designation from FDA for AMT-011 for the treatment of lipoprotein lipase deficiency. Amsterdam Molecular Therapeutics BV PRESS RELEASE 2007 June 04
9. AMT announces positive interim clinical data on its lead product AMT-011. Amsterdam Molecular Therapeutics BV PRESS RELEASE 2008 May 30
10. AMT intends to incorporate additional data to its marketing authorization dossier for Glybera. Amsterdam Molecular Therapeutics BV PRESS RELEASE 2008 October 03
11. Meeting highlights from the Paediatric Committee, 15-17 October 2008. European Medicines Agency PRESS RELEASE 2008 October 24
12. AMT: Glybera lowers pancreatitis incidence significantly. Amsterdam Molecular Therapeutics BV PRESS RELEASE 2009 January 28
13. AMT starts preregistration trial for Glybera. Amsterdam Molecular Therapeutics BV PRESS RELEASE 2009 May 07
14. AAV1-LPL (S447X) gene therapy reduces hypertriglyceridemia in ApoE2 knock in mice. Rip J, van Dijk KW, Sierts JA, Kastelein JJP, Twisk J, Kuivenhoven JA BIOCHIM BIOPHYS ACTA MOL CELL BIOL LIPIDS 2006 1761 10 1163-1168
15. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Ross CJD, Twisk J, Bakker AC, Miao F, Verbart D, Rip J, Godbey T, Dijkhuizen P, Hermens WTJMC, Kastelein JJP, Kuivenhoven JA et al HUM GENE THER 2006 17 5 487-499
16. Gene therapy for lipoprotein lipase deficiency: Working toward clinical application. Rip J, Nierman MC, Sierts JA, Petersen W, Van den Oever K, Van Raalte D, Ross CJD, Hayden MR, Bakker AC, Dijkhuizen P, Hermens WT et al HUM GENE THER 2005 16 11 1276-1286 (Pubitemid 41611655)
17. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPLS447X beneficial mutation. Ross CJD, Twisk J, Meulenberg JM, Liu GQ, van den Oever K, Moraal E, Hermens WT, Rip J, Kastelein JJP, Kuivenhoven JA, Hayden MR HUM GENE THER 2004 15 9 906-919
18. Long-term correction of murine lipoprotein lipase (LPL) deficiency by a single intramuscular administration of AAV1-LPLS447X. Ross CJ, Twisk J, Kuivenhoven JA, Liu GQG, Miao F, Scheenhart-van der Meer JW, Bakker A, Moraal E, Oranje PP, Hermens WT, Kastelein JJ et al CIRCULATION 2003 107 19 E143
19. Glybera shows long-term health benefits. Amsterdam Molecular Therapeutics BV PRESS RELEASE 2009 June 18
20. Adeno-associated virus LPLS447X gene therapy in LDL receptor knockout mice. Rip J, Sierts JA, Vaessen SFC, Kastelein JJP, Twisk J, Kuivenhoven JA ATHEROSCLEROSIS 2007 194 1 55-61
21. Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Ross CJD, Liu GQ, Kuivenhoven JA, Twisk J, Rip J, van Dop W, Excoffon KJDA, Lewis SME, Kastelein JJ, Hayden MR ARTERIOSCLER THROMB VASC BIOL 2005 25 10 2143-2150
22. Long-term correction of murine lipoprotein lipase deficiency by single intramuscular administration of AAV1- LPLS447X. Ross CJD, Meulenberg JJM, Twisk J, Kuivenhoven JA, Liu GQG, Miao FD, Moraal E, Oranje PPA, Bakker A, Hermens WTJMC, Scheenhart-van der Meer JJW et al MOL THER 2003 7 Abs 56
23. Correction of dyslipidemia in murine and feline models of lipoprotein lipase deficiency by intramuscular administration of AAV1-LPLS447X. Ross CJD, Twisk J, Kuivenhoven JA, Liu GQ, Miao FD, van den Oever K, Beetz M, Verbart D, Bakker A, Oranje PPA, Hermens WT et al MOL THER 2004 9 Abs 40
24. Treatment of female mice with AAV1-LPLS447X at 4 weeks prior to mating has no effect on reproductive potential and does not result in embryotoxicity or germ line transmission. Van Amersfoort E, Waalkens-Berendsen I, Bauer U, Meulenberg J, Twisk J HUM GENE THER 2007 18 10 Or 51
25. Biodistribution of AAV1-LPLS447X (AMT-010) vector sequences after intramuscular administration to lipoprotein lipase-deficient patients. Nierman M, Twisk J, Hermens W, Bakker AC, van Deventer S, Rekke B, Kastelein J, Stroes E, Kuivenhoven JA, Meulenberg J HUM GENE THER 2007 18 10 Or 50
26. Lipoprotein-lipase - Structure, function and mechanism of action. Santamarina-Fojo S, Brewer HB Jr INT J CLIN LAB RES 1994 24 3 143-147
27. Familial lipoprotein lipase deficiency, Apo C-II deficiency, and hepatic lipase deficiency. Brunzell JD, Deeb SS THE METABOLIC & MOLECULAR BASES OF INHERITED DISEASE (EDS: SCRIVER CR, BEAUDET AL, VALLE D, SLY WS) 2001 McGraw-Hill, New York, NY, USA 8th Edition 2789-2816
28. Primary lipoprotein-lipase-activity deficiency: Clinical investigation of a French-Canadian population. Gagne C, Brun LD, Julien P, Moorjani S, Lupien PJ CMAJ 1989 140 4 405-411
29. Hypertriglyceridemia: Its etiology, effects and treatment. Yuan G, Al-Shali KZ, Hegele RA CMAJ 2007 176 8 1113-1120
30. Structure of the human lipoprotein lipase gene. Deeb SS, Peng RL BIOCHEMISTRY 1989 28 10 4131-4135
31. Lipoprotein lipase: Genetics, lipid uptake, and regulation. Merkel M, Eckel RH, Goldberg IJ J LIPID RES 2002 43 12 1997-2006
32. Homozygous missense mutation (G56R) in glycosylphosphatidylinositol- anchored high-density lipoproteinbinding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Wang J, Hegele RA LIPIDS HEALTH DIS 2007 6 23
33. Polygenic determinants of severe hypertriglyceridemia. Wang J, Ban MR, Zou GY, Cao HN, Lin T, Kennedy BA, Anand S, Yusuf S, Huff MW, Pollex RL, Hegele RA HUM MOL GENET 2008 17 18 2894-2899
34. Lipoprotein lipase S447X - A naturally occurring gain-offunction mutation. Rip J, Nierman MC, Ross CJ, Jukema JW, Hayden MR, Kastelein JJP, Stroes ESG, Kuivenhoven JA ARTERIOSCLER THROMB VASC BIOL 2006 26 6 1236-1245
35. Enhanced conversion of triglyceride-rich lipoproteins and increased low-density lipoprotein removal in LPLS447X carriers. Nierman MC, Prinsen BHCMT, Rip J, Veldman RJ, Kuivenhoven JA, Kastelein JJP, de Sain-van der Velden MGM, Stroes ESG ARTERIOSCLER THROMB VASC BIOL 2005 25 11 2410-2415
36. Carriers of the frequent lipoprotein lipase S447X variant exhibit enhanced postprandial apoprotein B-48 clearance. Nierman MC, Rip J, Kuivenhoven JA, van Raalte DH, Hutten BA, Sakai N, Kastelein JJP, Stroes ESG METAB CLIN EXP 2005 54 11 1499-1503
37. Enhanced apoB48 metabolism in lipoprotein lipase X447 homozygotes. Nierman MC, Rip J, Kuivenhoven JA, Sakai N, Kastelein JJ, de Sain-van der Velden MGM, Stroes ESG, Prinsen BHCMT ATHEROSCLEROSIS 2007 194 2 446-451
38. Overexpression of human lipoprotein-lipase in transgenic mice. Resistance to diet-induced hypertriglyceridemia and hypercholesterolemia. Shimada M, Shimano H, Gotoda T, Yamamoto K, Kawamura M, Inaba T, Yazaki Y, Yamada N J BIOL CHEM 1993 268 24 17924-17929
39. Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Shimada M, Ishibashi S, Inaba T, Yagyu H, Harada K, Osuga J, Ohashi K, Yazaki Y, Yamada N PROC NATL ACAD SCI USA 1996 93 14 7242-7246
40. Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice. Yagyu H, Ishibashi S, Chen Z, Osuga J, Okazaki M, Perrey S, Kitamine T, Shimada M, Ohashi K, Harada K, Shionoiri F et al J LIPID RES 1999 40 9 1677-1685
41. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, Maas MM, Zwinderman AH, Ross C, Aronica E, High KA et al ARTERIOSCLER THROMB VASC BIOL 2008 28 12 2303-2304
42. An open label, dose escalation study to assess the safety and efficacy of AAV1-LPL gene therapy with alipogene tiparvovec (AMT-011) for patients with severe hypertriglyceridemia due to lipoprotein lipase deficiency (LPLD). Gaudet D, Brisson D, Methot J, van Deventer S ATHEROSCLEROSIS SUPPL 2009 10 2 Abs 554
43. Correction of hypertriglyceridemia in lipoprotein lipase deficient cats by intramuscular administration of AAV1-LPLS447X. Ross CJD, Twisk J, Kuivenhoven J, Verbart D, Beetz M, Dijkhuizen P, Hermens W, Kastelein J, Meulenberg J, Hayden MR AM SOC HUM GENET 2004 54 Abs 274
44. From genes to therapies: AAV-mediated therapy for LPL deficiency. Ross CJ, Twisk J, Rip J , Nierman MC, Dijkhuizen P, Hermens WT, Meulenberg JM, Kastelein JJ, Kuivenhoven JA, Hayden MR CIRCULATION 2005 112 17 Abs 693
45. AAV1-mediated gene therapy for LPL deficiency. Ross C, Twisk J, Rip J, Nierman M, Dijkhuizen P, Hermens W, Meulenberg J, Kastelein J, Kuivenhoven J, Hayden M AM SOC HUM GENET 2005 55 Abs 201
46. Treatment of female mice with AAV1-LPLS447X at 4 weeks prior to mating has no effect on reproductive potential and does not result in embryotoxicity or germ line transmission. Van Amersfoort ES, Waalkens-Berendsen IH, Bauer U, Sijtsma J, Meulenberg JJM, Twisk J AM SOC GENE THER 2008 11 Abs 791
47. Gene therapy for genetic lipoprotein lipase (LPL) deficiency; an update. Rip J, Nierman MC, Sierts JA, Ross CJ, Hayden MR, de Jong A, Dijkhuizen P, Hermens W, Twisk J, Kastelein JJ, Kuivenhoven JA et al AM SOC GENE THER 2005 8 Abs 907
48. Biodistribution of AAV1-LPLS447X vector sequences after intramuscular administration to lipoprotein lipase deficient patients. Nierman MC, Twisk J, Hermens WT, Bakker AC, Marieke B, van Deventer SJ, Rekke B, Kastelein JJ, Stroes ES, Kuivenhoven JA, Meulenberg JJ AM SOC GENE THER 2007 10 Abs 348
49. Biodistribution of AAV1-LPLS447X vector co-administered with immunosuppression to lipoprotein lipase deficient patients in a phase II study. Gaudet D, Methot J, Essiembre C, Brisson D, van Deventer S, Kleefstra A, Meulenberg J AM SOC GENE THER 2008 11 Abs 985
50. Safety and efficacy of AMT-010 gene therapy in lipoprotein lipase deficiency (LPLD). Stroes E, Kuivenhoven J, van Deventer S, Kastelein J ATHEROSCLEROSIS SUPPL 2009 10 2 P475
51. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Mingozzi F, Meulenberg FJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA, Hutnick NA, Betts MR, Kastelein JJ, Stroes ES, High KA BLOOD 2009 114 10 2077-2086
52. Gene transfer safety symposium: Immune responses to adeno-associated virus vectors. Session II: Immune responses in clinical studies using AAV vectors. Immune responses in a lipoprotein lipase deficiency study using AAV-1-LPLS447X. Office of Biotechnology Activities, Office of the Director, NIH US DEPARTMENT HEALTH HUM SERVICES 2007 June 19 4-5
53. Evaluation of recombinant AAV1 produced in insect cells in muscle-derived gene transfer. Twisk J, Ross CJD, Comijn L, Biesmans D, Haast S, Bakker AC, van Amersfoort ES, van Deventer SJH, Meulenberg JJM, Hayden MR, Hermens WTJMC EUR SOC GENE CELL THER ANN CONGRESS 2007 30 October P180
54. Product pipeline. Amsterdam Molecular Therapeutics BV COMPANY WORLD WIDE WEB SITE 2009 October 01
55. Amsterdam Molecular Therapeutics. Amsterdam Molecular Therapeutics BV INT BIOTECHNOL CONV & EXHIB 2009 May 21
56. Gene therapy for genetic lipid disorders: Lipoprotein lipase deficiency as a paradigm. Rader DJ NETH J MED 2005 63 1 2-3
57. An 18-year-old woman with familial chylomicronaemia who would not stick to a diet. Gasbarrini G, Mingrone G, Greco AV, Castagneto M LANCET 1996 348 9030 794
58. Novel LPL mutations associated with lipoprotein lipase deficiency: Two case reports and a literature review. Rahalkar AR, Giffen F, Har B, Ho J, Morrison KM, Hill J, Wang J, Hegele RA, Joy T CAN J PHYSIOL PHARMACOL 2009 87 3 151-160
59. Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Péterfy M, Ben-Zeev O, Mao HZ, Weissglas-Volkov D, Aouizerat BE, Pullinger CR, Frost PH, Kane JP, Malloy MJ, Reue K, Pajukanta P et al NAT GENET 2007 39 12 1483-1487
60. AAV1-LPLS447X gene therapy with alipogene tiparvovec prevents pancreatitis in lipoprotein lipase deficiency. Franssen R, Gaudet D, Stroes ES, Kastelein JP, Brisson D, Rousseau S, De Wal J, Van Deventer SJ Circulation 2009 120 18S Abs 2093-OR
61. AMT provides business update for the third quarter 2009. Amsterdam Molecular Therapeutics BV PRESS RELEASE 2009 November 18
62. Leading the way in gene therapy. Amsterdam Molecular Therapeutics BV COMPANY PRESENTATION 2009 November